These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. P450BM-3; a tale of two domains--or is it three? Peterson JA; Sevrioukova I; Truan G; Graham-Lorence SE Steroids; 1997 Jan; 62(1):117-23. PubMed ID: 9029725 [TBL] [Abstract][Full Text] [Related]
5. Indole hydroxylation by bacterial cytochrome P450 BM-3 and modulation of activity by cumene hydroperoxide. Li QS; Ogawa J; Schmid RD; Shimizu S Biosci Biotechnol Biochem; 2005 Feb; 69(2):293-300. PubMed ID: 15725653 [TBL] [Abstract][Full Text] [Related]
6. Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity. Behrendorff JB; Huang W; Gillam EM Biochem J; 2015 Apr; 467(1):1-15. PubMed ID: 25793416 [TBL] [Abstract][Full Text] [Related]
7. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. Velazquez MNR; Parween S; Udhane SS; Pandey AV Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914 [TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes). Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472 [TBL] [Abstract][Full Text] [Related]
9. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity. Hanna IH; Krauser JA; Cai H; Kim MS; Guengerich FP J Biol Chem; 2001 Oct; 276(43):39553-61. PubMed ID: 11509577 [TBL] [Abstract][Full Text] [Related]
11. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000 [TBL] [Abstract][Full Text] [Related]
12. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Chen Y; Liu L; Nguyen K; Fretland AJ Drug Metab Dispos; 2011 Mar; 39(3):373-82. PubMed ID: 21148079 [TBL] [Abstract][Full Text] [Related]
13. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348 [TBL] [Abstract][Full Text] [Related]
14. Differential effect of copper (II) on the cytochrome P450 enzymes and NADPH-cytochrome P450 reductase: inhibition of cytochrome P450-catalyzed reactions by copper (II) ion. Kim JS; Ahn T; Yim SK; Yun CH Biochemistry; 2002 Jul; 41(30):9438-47. PubMed ID: 12135366 [TBL] [Abstract][Full Text] [Related]
15. Use of chemical auxiliaries to control p450 enzymes for predictable oxidations at unactivated C-h bonds of substrates. Auclair K; Polic V Adv Exp Med Biol; 2015; 851():209-28. PubMed ID: 26002737 [TBL] [Abstract][Full Text] [Related]
16. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Uttamsingh V; Lu C; Miwa G; Gan LS Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous detection of NADPH consumption and H Morlock LK; Böttcher D; Bornscheuer UT Appl Microbiol Biotechnol; 2018 Jan; 102(2):985-994. PubMed ID: 29150709 [TBL] [Abstract][Full Text] [Related]